近年来诊断技术的进展,使人们比较容易地证实心律失常,但是药物疗法仍是一个困难的问题。目前有一些新药在控制心律失常上确实很有希望,其中有许多药在美国尚未被普遍应用,但对这些药物的疗效和副作用已有了较多的认识。 Bretylium(溴苄乙胺) Bretylium最初当作抗高血压使用,1965年开始用于治疗室性心律失常。这种药是一种肾上腺素能神经阻滞剂,能提高室颤阈,也可通过化学作用将室颤转变为窦性节律。虽然,此药最初认为是治疗心肌梗塞伴 Advances in diagnostic techniques in recent years have made it easier to verify cardiac arrhythmias, but drug therapy remains a difficult issue. There are some new drugs in the control of arrhythmias really promising, many of which have not yet been widely used in the United States, but the efficacy of these drugs and side effects have been more understanding. Bretylium Bretylium was originally used as an antihypertensive agent and was used in 1965 to treat ventricular arrhythmias. The drug is an adrenergic blocker that increases the threshold of ventricular fibrillation and converts chemical fibrillation into sinus rhythm. Although, this medicine was originally thought to treat myocardial infarction